Harvard-Broad Genome Editing Technologies Fund

The first application deadline is September 17, 2021 at 5pm EST.

apply now


The newly established Harvard-Broad Genome Editing Technologies Fund will support research that improves on existing genome-editing technologies, identifies delivery mechanisms for these technologies, and applies these technologies to the understanding and treatment of rare genetic diseases. As defined by NIH, rare diseases in the United States are those that affect fewer than 200,000 people.[1]

Available Funding

Budget requests are not limited. Approximately $2M will be available annually for awards made through this program. This funding can support any expenses related to the cost of performing research over a 15-month project period. Eligible expenses include: research; associated travel costs; the publication and dissemination of findings; and support for undergraduate, graduate and postdoctoral scholars.


Ladder faculty members in Harvard’s Faculty of Arts & Sciences (FAS) and the John A. Paulson School of Engineering & Applied Sciences (SEAS) are eligible to apply. Single- and multi-investigator projects are welcome.

Application Instructions

Applications must be submitted through the Harvard University Funding Portal. To apply, please submit:

1. A one- to two-page proposal (one-inch margins, 11-point font or larger, PDF format) that briefly describes the proposed research project. A one-page appendix with graphics and/or references (optional, PDF format) may be included in addition to the one- to two-page project proposal.

2. Detailed budget for the requested funds (PDF format). There is no prescribed format for the budget request. Faculty are encouraged to work closely with their grant administrators to develop a budget. School assessments and/or indirect costs should not be included in the budget request (these will be accounted for at the time of award). Applicants may request funding to support any expenses related to the cost of performing research over a 15-month project period. The funding period may begin as early as November 1, 2021.

3. Two-page biosketch (PDF format) for the Principal Investigator. In addition, applicants may submit a two-page biosketch for any collaborators involved in the project.

Review Criteria

Proposals will be evaluated on their intellectual merit, innovation, design, feasibility and likely impact on the study of rare diseases.

A small committee of senior faculty members will review submitted proposals. The review committee is made up of:

Steven E. Hyman (Committee Chair), Director of the Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard; core member of the Broad; and Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology

Mark Fishman, Professor in the Harvard Department of Stem Cell and Regenerative Biology; and Chief of the Pathways Clinical Service, Massachusetts General Hospital

Dan Kahne, Higgins Professor of Chemistry and Chemical Biology, Harvard University


The initial deadline for receipt of applications is September 17, 2021 at 5pm EST. Funding decisions will be announced in early October 2021. Proposals will be solicited annually by this program.


Please contact Jennifer Corby, Research Development Officer (jcorby@fas.harvard.edu) or Susan Gomes, Director of Research Development and Strategy (susan_gomes@harvard.edu) for more information about this program.



[1] NIH NCATS Genetic and Rare Diseases Information Center, https://rarediseases.info.nih.gov/diseases.